PMV Pharma shareholders elect directors, approve say-on-pay, and ratify auditor

Proposal 2. Non-Binding Advisory Vote to Approve the Compensation of the Company’s Named Executive Officers The Company’s stockholders approved, on a non-binding advisory basis, the compensation paid to its named executive officers as described in the Company’s definitive proxy statement on Schedule 14A, filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 28, 2023 (the “Proxy Statement”). The final voting results are as follows: FOR AGAINST ABSTAIN BROKER NON-VOTE 34,537,890 836,543 1,065 4,491,578

Proposal 1. Election of Directors The Company’s stockholders elected the three persons listed below as Class III Directors, each to serve until the Company’s 2026 Annual Meeting of Stockholders and until their respective successors has been duly elected and qualified, or until the earlier of the respective director’s death, resignation or removal. The final voting results are as follows: FOR WITHHELD BROKER NON-VOTE Richard Heyman, Ph.D. 28,709,696 6,665,802 4,491,578 David H. Mack, Ph.D. 35,181,696 193,802 4,491,578 Laurie Stelzer 34,128,780 1,246,718 4,491,578

Proposal 3. Ratification of Independent Registered Public Accounting Firm The Company’s stockholders ratified the selection by the Audit Committee of the Company’s Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The final voting results are as follows: FOR AGAINST ABSTAIN 39,864,451 2,087 538